HOME    SEARCH    ABOUT US    CONTACT US    HELP   
           
Prev Next

24.174.1412    ADDITIONS, DELETIONS, AND RESCHEDULING OF DANGEROUS DRUGS

(1) In addition to those dangerous drugs scheduled in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA, the board adds the following to dangerous drug schedules after considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA:

(a) Schedule I:

(i) none at this time;

(b) Schedule II:

(i) norfentanyl;

(c) Schedule III:

(i) none at this time;

(d) Schedule IV:

(i) brexanolone, allopregnanolone;

(ii) soriamfetol;

(iii) lemborexant;

(e) Schedule V:

(i) lasmiditan;

(ii) cenobamate.

(2) The board deletes the following dangerous drugs from the schedules in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA, after considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA:

(a) Schedule I:

(i) none at this time;

(b) Schedule II:

(i) 6β-naltrexol;

(c) Schedule III:

(i) none at this time;

(d) Schedule IV:

(i) none at this time;

(e) Schedule V:

(i) approved cannabidiol drugs.  A drug product in finished dosage formulation that has been approved by the United States Food and Drug Administration that contains cannabidiol, also known as (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol), derived from cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols, and as authorized by the Agriculture Improvement Act of 2018 (P.L. 115-334).

(3) After considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA, the board reschedules the following dangerous drugs from those scheduled in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA:

(a) Schedule I:

(i) none at this time;

(b) Schedule II:

(i) none at this time;

(c) Schedule III:

(i) none at this time;

(d) Schedule IV:

(i) none at this time;

(e) Schedule V:

(i) none at this time.

 

History: 50-32-103, 50-32-203, MCA; IMP, 50-32-103, 50-32-202, 50-32-203, 50-32-209, 50-32-222, 50-32-223, 50-32-224, 50-32-225, 50-32-226, 50-32-228, 50-32-229, 50-32-231, 50-32-232, MCA; NEW, Eff. 9/16/71; EMERG, AMD, Eff. 5/5/74; AMD, Eff. 9/4/75; AMD, Eff. 2/5/76; AMD, Eff. 3/7/76; AMD, Eff. 4/5/76; AMD, Eff. 9/5/76; AMD, 1978 MAR p. 393, Eff. 3/25/78; AMD, 1978 MAR p. 1740, Eff. 12/29/78; AMD, 1979 MAR p. 199, Eff. 3/1/79; AMD, 1980 MAR p. 1720, Eff. 6/27/80; AMD, 1981 MAR p. 625, Eff. 6/26/81; TRANS, from Dept. of Prof. & Occup. Lic., Ch. 274, L. 1981, Eff. 7/1/81; AMD, 1984 MAR p. 589, Eff. 4/13/84; AMD, 1984 MAR p. 1567, Eff. 10/26/84; AMD, 1985 MAR p. 1017, Eff. 7/16/85; AMD, 1986 MAR p. 1957, Eff. 11/29/86; AMD, 1988 MAR p. 271, Eff. 2/12/88; AMD, 1989 MAR p. 1193, Eff. 8/18/89; AMD, 1995 MAR p. 2689, Eff. 12/8/95; AMD, 1999 MAR p. 344, Eff. 11/20/98; AMD, 2002 MAR p. 178, Eff. 2/1/02; TRANS, from Commerce, 2002 MAR p. 904; AMD, 2010 MAR p. 2968, Eff. 12/24/10; AMD, 2015 MAR p. 1491, Eff. 9/25/15; AMD, 2021 MAR p. 1671, Eff. 11/20/21.

Home  |   Search  |   About Us  |   Contact Us  |   Help  |   Disclaimer  |   Privacy & Security